東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"Drugs- Side effects." ]

切換: 標籤 | MARC模式 | ISBD

Cardiovascular safety in drug develo...

Turner, J. Rick.

FindBook

Google Book

Amazon

博客來

Cardiovascular safety in drug development and therapeutic use = new methodologies and evolving regulatory landscapes /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Cardiovascular safety in drug development and therapeutic use/ by J. Rick Turner, Dilip R. Karnad, Snehal Kothari.
其他題名:	new methodologies and evolving regulatory landscapes /
作者:	Turner, J. Rick.
其他作者:	Karnad, Dilip R.
出版者:	Cham :Springer International Publishing : : 2017.,
面頁冊數:	xxvi, 333 p. :ill., digital ;24 cm.
內容註:	The Central Importance of Cardiovascular Safety in Contemporary New Drug Development -- The Biological Basis of Drug Responses -- Cardiovascular Structure, Function, Pathophysiology, & Disease -- The Current Regulatory Landscape -- The "Comprehensive In Vitro Proarrhythmia Assay" Initiative -- The "Early ECG Assessment" Initiative -- The "Submission of Extended Digital ECG Data" Initiative -- Meta-analysis and Meta-methodology -- Current Regulatory Landscapes and their Potential Evolution -- Off-target Blood Pressure Responses to Non-cardiovascular Drugs -- Oncology Drug Development and Therapeutics: Cardiotoxicity Considerations -- Postmarketing Surveillance -- Regulatory Perspectives on General Drug Safety -- Future Directions in Cardiovascular Safety -- References.
Contained By:	Springer eBooks
標題:	Drugs - Side effects. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-40347-2
ISBN:	9783319403472

Cardiovascular safety in drug development and therapeutic use = new methodologies and evolving regulatory landscapes /
Turner, J. Rick.

Cardiovascular safety in drug development and therapeutic usenew methodologies and evolving regulatory landscapes /[electronic resource] :by J. Rick Turner, Dilip R. Karnad, Snehal Kothari. - Cham :Springer International Publishing :2017. - xxvi, 333 p. :ill., digital ;24 cm.

The Central Importance of Cardiovascular Safety in Contemporary New Drug Development -- The Biological Basis of Drug Responses -- Cardiovascular Structure, Function, Pathophysiology, & Disease -- The Current Regulatory Landscape -- The "Comprehensive In Vitro Proarrhythmia Assay" Initiative -- The "Early ECG Assessment" Initiative -- The "Submission of Extended Digital ECG Data" Initiative -- Meta-analysis and Meta-methodology -- Current Regulatory Landscapes and their Potential Evolution -- Off-target Blood Pressure Responses to Non-cardiovascular Drugs -- Oncology Drug Development and Therapeutics: Cardiotoxicity Considerations -- Postmarketing Surveillance -- Regulatory Perspectives on General Drug Safety -- Future Directions in Cardiovascular Safety -- References.

With the advent of multiple new therapeutic agents for a variety of important diseases has come an increasing realization that many of these drugs can have adverse effects on the heart and vascular system. As this book so elegantly details the mechanisms by which harm occurs are highly complex, many times predictable, but always clinically relevant. Notable experts in the field of cardiovascular medicine, such as Drs. Turner, Karnad, and Kothari, have turned their attention to this thorny problem, and begun to dissect the diverse mechanisms by which cardiac harm can occur with a variety of non-cardiac drugs. This is no easy task, given the complexity of the diseases we treat, and the wide spectrum of new therapies we seek to apply. However, it is an issue with which all health care providers must become familiar in order to prescribe appropriate therapy while safeguarding patients against avoidable and life-threatening cardiac adverse effects. This compendium represents the state-of-the-art in the evolving field of cardiac safety and is vital reading for those interested in developing new chemical entities, as well as those who prescribe them and monitor patients for their hazard. As such, I recommend this book as essential reading for students, scientists, and health care providers at all levels of training. Peter R. Kowey, MD, FACC, FAHA, FHRS Lankenau Institute for Medical Research & Thomas Jefferson University.

ISBN: 9783319403472

Standard No.: 10.1007/978-3-319-40347-2doiSubjects--Topical Terms:

789547
Drugs
--Side effects.

LC Class. No.: RM302.5

Dewey Class. No.: 615.7042

Cardiovascular safety in drug development and therapeutic use = new methodologies and evolving regulatory landscapes /
LDR:03232nmm a2200313 a 4500 001 2087518
003 DE-He213
005 20160728175802.0
006 m d
007 cr nn 008maaau
008 171013s2017 gw s 0 eng d
020 $a 9783319403472 $q (electronic bk.)
020 $a 9783319403458 $q (paper)
024 7 $a 10.1007/978-3-319-40347-2 $2 doi
035 $a 978-3-319-40347-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RM302.5
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 615.7042 $2 23
090 $a RM302.5 $b .T948 2017
100 1 $a Turner, J. Rick. $3 744266
245 1 0 $a Cardiovascular safety in drug development and therapeutic use $h [electronic resource] : $b new methodologies and evolving regulatory landscapes / $c by J. Rick Turner, Dilip R. Karnad, Snehal Kothari.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2017.
300 $a xxvi, 333 p. : $b ill., digital ; $c 24 cm.
505 0 $a The Central Importance of Cardiovascular Safety in Contemporary New Drug Development -- The Biological Basis of Drug Responses -- Cardiovascular Structure, Function, Pathophysiology, & Disease -- The Current Regulatory Landscape -- The "Comprehensive In Vitro Proarrhythmia Assay" Initiative -- The "Early ECG Assessment" Initiative -- The "Submission of Extended Digital ECG Data" Initiative -- Meta-analysis and Meta-methodology -- Current Regulatory Landscapes and their Potential Evolution -- Off-target Blood Pressure Responses to Non-cardiovascular Drugs -- Oncology Drug Development and Therapeutics: Cardiotoxicity Considerations -- Postmarketing Surveillance -- Regulatory Perspectives on General Drug Safety -- Future Directions in Cardiovascular Safety -- References.
520 $a With the advent of multiple new therapeutic agents for a variety of important diseases has come an increasing realization that many of these drugs can have adverse effects on the heart and vascular system. As this book so elegantly details the mechanisms by which harm occurs are highly complex, many times predictable, but always clinically relevant. Notable experts in the field of cardiovascular medicine, such as Drs. Turner, Karnad, and Kothari, have turned their attention to this thorny problem, and begun to dissect the diverse mechanisms by which cardiac harm can occur with a variety of non-cardiac drugs. This is no easy task, given the complexity of the diseases we treat, and the wide spectrum of new therapies we seek to apply. However, it is an issue with which all health care providers must become familiar in order to prescribe appropriate therapy while safeguarding patients against avoidable and life-threatening cardiac adverse effects. This compendium represents the state-of-the-art in the evolving field of cardiac safety and is vital reading for those interested in developing new chemical entities, as well as those who prescribe them and monitor patients for their hazard. As such, I recommend this book as essential reading for students, scientists, and health care providers at all levels of training. Peter R. Kowey, MD, FACC, FAHA, FHRS Lankenau Institute for Medical Research & Thomas Jefferson University.
650 0 $a Drugs $x Side effects. $3 789547
650 0 $a Drug development. $3 716904
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Drug Safety and Pharmacovigilance. $3 2108855
650 2 4 $a Cardiology. $3 861477
700 1 $a Karnad, Dilip R. $3 3216464
700 1 $a Kothari, Snehal. $3 3216465
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-40347-2
950 $a Medicine (Springer-11650)